Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
References (20)
- Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998;51(3):237–254. PubMed CrossRef
- Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16(suppl 2):54S–59S, discussion 59S–61S. PubMed CrossRef
- Selvaraj V, Gunasekar P, Kumar S, et al. Urinary incontinence due to overactive detrusor muscle: a rare side effect of venlafaxine. Case Rep Urol. 2015;2015:690931. PubMed CrossRef
- Polimeni G, Salvo F, Cutroneo P, et al. Venlafaxine-induced urinary incontinence resolved after switching to sertraline. Clin Neuropharmacol. 2005;28(5):247–248. PubMed CrossRef
- Cavanaugh GL, Martin RE, Stenson MA, et al. Venlafaxine and urinary incontinence: possible association. Ann Pharmacother. 1997;31(3):372. PubMed CrossRef
- Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(6):386–388. PubMed CrossRef
- Hansen LK. Venlafaxine-induced increase in urinary frequency in 3 women. J Clin Psychiatry. 2004;65(6):877–878. PubMed CrossRef
- Inghilleri M, Conte A, Frasca V, et al. Venlafaxine and bladder function. Clin Neuropharmacol. 2005;28(6):270–273. PubMed CrossRef
- Tuman TC. Venlafaxine-induced urinary retention. Prim Care Companion CNS Disord. 2021;23(1):20l02702. PubMed CrossRef
- Demirdöğen ŞO, Yıldırım Demirdöğen E, Adanur Ş. Acute urinary retention after venlafaxine use. Arch Ital Urol Androl. 2017;89(2):160–161. PubMed CrossRef
- Benazzi F. Urinary retention with venlafaxine‐fluoxetine combination. Hum Psychopharmacol. 1998;13(2):139–140. CrossRef
- World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). 1992.
- Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314, discussion 1314–1315. PubMed CrossRef
- Norton PA, Zinner NR, Yalcin I, et al; Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002;187(1):40–48. PubMed CrossRef
- Katofiasc MA, Nissen J, Audia JE, et al. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci. 2002;71(11):1227–1236. PubMed CrossRef
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. PubMed CrossRef
- Stahl SM. Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology? CNS Spectr. 2008;13(2):115–118. PubMed CrossRef
- Lenze EJ. Reversal of SSRI-associated urinary retention with mirtazapine augmentation. J Clin Psychopharmacol. 2012;32(3):434. PubMed CrossRef
- Thor KB, Katofiasc MA, Danuser H, et al. The role of 5-HT(1A) receptors in control of lower urinary tract function in cats. Brain Res. 2002;946(2):290–297. PubMed CrossRef
- Delbressine LP, Vos RM. The clinical relevance of preclinical data: mirtazapine, a model compound. J Clin Psychopharmacol. 1997;17(suppl 1):29S–33S. PubMed CrossRef
Please sign in or purchase this PDF for $40.